Beta Drugs Limited announced that its board of directors has approved several key decisions during its meeting held on January 9, 2026.

These decisions include the alteration of the company's memorandum of association to increase authorized share capital and the adoption of the "Beta Drugs Limited Employee Stock Option Plan 2026," which allows for the creation and grant of up to 2,00,000 stock options.

A significant development is the acquisition of 66.09% of the equity share capital in Nivian Life Sciences Private Limited for a total consideration of ₹69.39 crore. This acquisition involves a purchase of equity shares from existing shareholders, with a share purchase agreement and shareholders' agreement executed on January 9, 2026. The consideration will be paid through a combination of cash (₹20.81 crore) and a share swap arrangement, involving the issuance of 2,83,668 equity shares of Beta Drugs at ₹1,712.49 per share.

Nivian Life Sciences operates in the pharmaceutical marketing and sales sector, specifically in In-Vitro Fertilisation (IVF) therapy, and reported a turnover of ₹29.12 crore and an EBIDTA of ₹4.22 crore for FY25.

To facilitate these transactions, an extra-ordinary general meeting (EGM) of the company's members has been convened for February 4, 2026, to seek shareholder approval.

The company's board meeting commenced at 10:00 AM and concluded at 5:00 PM on January 9, 2026.